Drug Profile


Alternative Names: AZQ; CI 904; NSC 182986

Latest Information Update: 30 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA); Nonindustrial source
  • Developer National Institutes of Health (USA)
  • Class Aziridines; Benzoquinones; Cytostatics; Small molecules
  • Mechanism of Action Alkylating agents; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported CNS cancer

Most Recent Events

  • 08 Jul 1999 Discontinued-III for CNS cancer in USA (IV)
  • 02 Jun 1995 A study has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top